Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease

• Published in: International journal of cardiology 2005-02, Vol.98 (3), p.479-486
• Main Authors: Lemos, Pedro A., de Feyter, Pim J., Serruys, Patrick W., Saia, Francesco, Arampatzis, Chourmouzios A., Disco, Clemens, Mercado, Nestor, Mainar, Vicente, Morı́s, César, van den Bos, A.A., Berghoefer, Gunnar
• Format: Article
• Language: English
• Subjects: Angioplasty; Angioplasty, Balloon, Coronary; Biological and medical sciences; Cardiology. Vascular system; Cholesterol; Coronary Artery Disease - epidemiology; Coronary disease; Coronary Disease - drug therapy; Coronary Disease - therapy; Coronary heart disease; Fatty Acids, Monounsaturated - therapeutic use; Heart; HMG-CoA reductase inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Indoles - therapeutic use; Medical sciences; Proportional Hazards Models; Risk Assessment; Stents
• ISSN: 0167-5273; 1874-1754
• DOI: 10.1016/j.ijcard.2003.11.031

Background: To evaluate the impact of the extent of coronary disease (single- or multivessel) and of fluvastatin treatment on the incidence of long-term cardiac atherosclerotic complications in the Lescol Intervention Prevention Study (LIPS). Methods: A total of 1063 patients with single-vessel disease and 614 patients with multivessel disease were randomized to receive fluvastatin (40 mg bid) or placebo for at least 3 years following a first successful percutaneous coronary intervention. The incidence of cardiac atherosclerotic events (cardiac death, non-fatal myocardial infarction, and coronary re-interventions not related to restenosis) was evaluated. Results: Patients with multivessel disease tended to be older and presented a higher prevalence of associated risk factors and cardiovascular antecedents. The presence of multivessel disease markedly increased the risk of cardiac atherosclerotic events compared with single-vessel disease among patients allocated to placebo (RR 1.67 [95% CI: 1.24–2.25]; p